20-hydroxyecdysone
20-Hydroxyecdysone is a naturally occurring ecdysteroid hormone, which is marketed as dietary supplements that can increase strength and muscle mass during resistance training, particularly bodybuilding. It was found, that 20-hydroxyecdysone did not affect body composition or training adaptations nor did they influence the anabolic/catabolic hormone status or general markers of catabolism in resistance-trained males. Because is known, that ecdysteroids have been shown to prevent various changes in mammalian tissues after female sex hormone deprivation. 20-Hydroxyecdysone also was investigated on these properties. It was found in rats, that 20-Hydroxyecdysone had a beneficial effect on reducing blood pressure and consequently preventing dilated cardiac hypertrophy. Some in vitro experiments showed, that 20-hydroxyecdysone had effects on lymphocytes and neutrophils, and may act as an immunomodulator. — NCATS
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started May 24, 2018 (NCT03452488)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C- Mol. weight
- 480.6341 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- Wikipedia20-Hydroxyecdysone ↗
- NCATS779A7KPL0Y ↗
- ChEMBLCHEMBL224128 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04827537 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2021 | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan |
| NCT04472728 | Phase 2/Phase 3 (Phase 3) | Jun 16, 2020 | Biophytis, Sorbonne University |
| NCT03906201 | N/A | Feb 6, 2019 | University of Guadalajara |
| NCT03452488 | Phase 2 | May 24, 2018 | Biophytis |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biophytis | For profit | 2 | 2 | 2 | 2018 |
| Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Sorbonne University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Guadalajara | Academic/Hospital | 1 | 1 | 1 | 2019 |